Last spring, a 41-year-old CrossFit coach named Marcus in Austin told me he'd been running BPC-157 at 250 mcg daily for six straight months. "I felt great at week eight. By month five, I honestly couldn't tell if it was still doing anything, but I was afraid to stop." His prescriber had him pull labs, take eight weeks off, and reassess. His CRP, which had been slightly elevated at baseline, had drifted back to normal. His elbow tendinopathy stayed improved through the off-period. "Turns out the work was already done," he said. "I was just paying for peptides out of habit."
That anecdote captures the entire cycling debate in miniature. The standard practice with BPC-157 is to run it for a defined window (4 to 12 weeks), take an equivalent or longer break, then decide whether another round makes sense. This isn't based on some rigorous human trial that proved cycling is superior. It's a hedge, born from the simple fact that nobody has published long-term safety data on this peptide in humans.
BPC-157 is a research peptide. It is not FDA-approved. The protocols below reflect common practitioner patterns, not regulatory guidance.
The Real Reason Everybody Cycles
No published human study on BPC-157 extends beyond a few months. Animal research typically runs weeks. When you don't know what happens at month eight or year two, you build in pauses. That's the boring truth.
The specific theoretical worry: BPC-157 promotes angiogenesis (new blood vessel formation) and modulates growth factor signaling. Both of those processes are how your body repairs a torn tendon. They're also how solid tumors recruit their own blood supply. Nobody has shown that BPC-157 feeds tumors. But nobody has shown it doesn't over prolonged continuous exposure, either. Cycling creates a reset window. Think of it like crop rotation for your signaling pathways: you let the field go fallow so you can see what's actually growing.
There is no published evidence that continuous use causes harm. There is also no published evidence that continuous use is safe past 12 weeks. Cycling is the conservative default because the alternative is guessing.
4-Week Cycle: For Acute Injuries
Best fit: a fresh soft-tissue injury, short post-surgical recovery, or a situation where the repair window is naturally brief.
| Phase | Duration | Approach |
|---|---|---|
| On | 4 weeks | 250-500 mcg/day, sometimes front-loaded at the higher end for weeks 1-2 |
| Off | 4-8 weeks | No BPC-157. Reassess at end of off-period. |
This is the shortest cycle practitioners commonly use. If the tissue is going to respond, four weeks is usually enough time to see it. Stretching longer won't squeeze more benefit from an acute injury that's already on its healing trajectory.
8-Week Cycle: The Workhorse
Best fit: chronic gut conditions, persistent joint or tendon issues, general recovery protocols where four weeks feels too short.
Get provider-reviewed GLP-1 therapy
Side effects are manageable with the right support. A licensed provider can adjust your dose when you need it.
Start Free Assessment →| Phase | Duration | Approach |
|---|---|---|
| On | 8 weeks | 250-500 mcg/day, steady or with a mild taper in weeks 7-8 |
| Off | 4-8 weeks | Reassess for second cycle if warranted |
This is the most common template in practitioner-directed protocols, and for good reason. Most people who respond to BPC-157 report noticing clear changes by week four. Weeks five through eight let those changes consolidate. It's long enough to work, short enough to stay in cautious territory.
12-Week Cycle: The Long Play
Best fit: chronic tendinopathy that hasn't budged, IBD or stubborn gut conditions, slow-healing post-surgical cases.
| Phase | Duration | Approach |
|---|---|---|
| On | 12 weeks | 250 mcg/day, occasional taper in weeks 10-12 |
| Off | 8-12 weeks | Full off-cycle, often paired with lab work at the end |
Twelve weeks is the upper boundary of common practice. If you're considering anything longer, you've left the map. There is essentially no evidence base to guide you.
Loading vs. Flat Dosing
Two approaches, and honest practitioners will tell you neither has been proven superior in controlled settings.
Loading then maintenance: Start at a higher dose for the first one to two weeks, then drop to a lower maintenance dose. The idea is faster tissue saturation. Sounds logical. Hasn't been validated.
Flat dose: Same amount every day, start to finish. Simpler, more predictable, fewer math errors when reconstituting.
Here's the thing: flat dosing is the safer default for a first-time user. If you're going to experiment with loading, do it in a later cycle when you already know how your body responds to the baseline.
Should You Taper Off?
Some practitioners have patients cut the dose by 50% during the final week or two. The rationale is a smoother transition. There is no controlled evidence that tapering produces different outcomes than simply stopping.
That said, the psychological comfort of a taper isn't nothing. If it helps a patient feel less anxious about stopping, it costs almost nothing to do. Cut the dose in half for the last five to seven days and move on.
What the Off-Cycle Is Actually For
The off-cycle isn't just a gap in your calendar. It's the assessment phase, and skipping it is how people end up like Marcus, running peptides on autopilot.
During the off-cycle:
- Track whether your improvements hold, fade, or reverse entirely
- Pull follow-up labs if your protocol included baseline bloodwork
- Decide with your prescriber whether another cycle is warranted
- Adjust dose, route, or stacking strategy for the next round if needed
A common pattern: first cycle at 250 mcg/day, partial response, second cycle bumped to 500 mcg/day under prescriber direction. The off-cycle is what makes that decision intelligible instead of blind.
Repeating Cycles Over a Year
Some chronic conditions justify two or three cycles annually, with full off-periods between each one. In that pattern, total on-cycle time typically caps around 24 to 32 weeks per year.
Beyond that, the safety argument for quasi-continuous use gets thin. No published evidence supports indefinite cycling.
Why Year-Round Use Isn't Standard (Even If People Do It)
Continuous BPC-157 use, 365 days a year, gets promoted in certain fitness and biohacker circles. The pushback from the conservative side comes down to three points:
- No human safety data exists for continuous use beyond 12 weeks.
- The angiogenesis mechanism that repairs your tendon is the same mechanism tumors exploit to build vasculature. Continuous, uninterrupted activation of that pathway is not something anyone should assume is benign.
- The off-cycle is the only structural moment to evaluate whether you still need the protocol at all.
Continuous use isn't impossible. It's uncharacterized. And "uncharacterized" is a polite way of saying nobody knows what happens.
Cycling When You're Stacking
When BPC-157 is combined with other peptides, the default is to cycle everything together, unless the stack partner has its own established safety profile:
- BPC-157 + TB-500: Cycle together. Both lack long-term human data.
- BPC-157 + GHK-Cu: Cycle together for skin or wound protocols.
- BPC-157 + glutamine: Glutamine has an independent safety profile. It's fine to continue glutamine through the off-cycle.
Lab Work Across Multiple Cycles
For anyone running more than one cycle per year, a common practitioner-directed lab schedule looks like this:
- Before the first cycle: CBC, CMP, CRP, lipid panel
- End of each on-cycle: Repeat the same panel
- Mid off-cycle or annually: Repeat with additional markers if clinically indicated
None of this is BPC-157-specific testing (there isn't any). It's general health surveillance to catch unexpected signals early.
FAQ
How long should I cycle BPC-157? Most common cycles run 4 to 12 weeks on, with off-cycles of equivalent length. The 8-weeks-on, 4-to-8-weeks-off pattern is the most widely used default.
Can I run BPC-157 continuously? There is no published safety data for continuous use past 12 weeks. The conservative position, and the one most prescribers take, is to cycle.
How long should my off-cycle be? Most practitioners recommend an off-cycle at least equal to the on-cycle length, with four weeks as the absolute minimum.
Can I do back-to-back cycles? Some chronic conditions justify two to three cycles in a year with full off-periods between. Repeating cycles without a genuine off-period is not standard practice.
Should I cycle differently when stacking? Cycle the stack together unless the stack partner has its own established continuous-use safety profile (e.g., glutamine).
Do I need blood work between cycles? It's strongly recommended. Baseline labs before your first cycle and repeat panels at the end of each on-cycle give you and your prescriber actual data instead of guesswork.
Disclaimer
BPC-157 is a research peptide. It is not FDA-approved for any indication. The cycling templates above reflect common practitioner patterns and are not medical advice. Compounded BPC-157 is dispensed only when a licensed prescriber determines, in clinical judgment, that it is appropriate for the individual patient. Individual results vary.